共 141 条
[1]
Wilkinson GR(1995)Genetic polymorphism of S-mephenytoin hydroxylation Pharmacol Ther 43 53-76
[2]
Guengerich FP(1994)The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 15419-15422
[3]
Branch RA(1994)Biochemistry and molecular biology of the human CYP2C subfamily Pharmacogenetics 4 285-299
[4]
de Morais SM(2006)A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 103-113
[5]
Wilkinson GR(2010)Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations Eur J Clin Pharmacol 66 1199-1205
[6]
Blaisdell J(2001)Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin Clin Pharmacol Ther 69 108-113
[7]
Nakamura K(2008)Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians Br J Clin Pharmacol 65 752-760
[8]
Meyer U(2010)A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism Aliment Pharmacol Ther 31 150-159
[9]
Goldstein JA(2010)Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect Drug Metab Dispos 38 894-897
[10]
Goldstein JA(2010)Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole Eur J Clin Pharmacol 66 681-687